Alle Storys
Folgen
Keine Story von SYGNIS AG mehr verpassen.

SYGNIS AG

euro adhoc: LION Bioscience AG
Quarterly or Semiannual Financial Statements
LION to Revise Policy on Timing of Revenue Recognition for Software Licenses and Announces Preliminary Q3 Results (E)

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
LION to Revise Policy on Timing of Revenue Recognition for Software
Licenses and Announces Preliminary Q3 Results
Cambridge, MA, USA, Heidelberg, February 4, 2004 - LION bioscience AG
plans to revise its revenue recognition practice with respect to
certain software licenses and restate its results for prior fiscal
years. As part of LION’s most recent review of its revenue
recognition policy together with Ernst & Young AG, LION’s independent
auditors, LION determined that accounting guidance issued by the
American Institute of Certified Public Accountants (or AICPA) applies
to certain of LION’s software license agreements.
In prior years, LION had recognized the license revenue from
multi-year software licenses as well annual licenses upon entering
into the agreement and delivery of the software. LION has now
determined that revenue from license fees under these agreements
should be recognized ratably over the contractual term. Based on its
preliminary review LION expects that these revisions in accounting
policy will cause changes in revenue and earnings approximately as
follows:
FY 2000/2001: (2) million EUR; FY 2001/2002: (7) million EUR; FY
2002/2003: +/- 0 million EUR
This accounting revision will not affect cumulative revenue over the
past and future periods, other than the impact from currency exchange
rates. It does not involve the loss or change of any previously
reported software license, and there is no indication of any
accounting improprieties LION’s liquidity, cash flows are not
affected at all.
LION expects to delay issuance of its final nine-month interim report
for the current fiscal year presumably until the end of February
2004, while completing the adjusted financial information. The
following quarterly information reflects the new revenue recognition
policy and is preliminary only. LION expects total revenue of 16.6
million EUR for the nine-months period ending December 31, 2003
compared with 20.6 million EUR for the same period in the prior
fiscal year. Despite additional restructuring expenses in Q3 in the
amount of 2.6 million EUR, LION continues to reduce its losses; net
loss is expected to be 6.1 million EUR for Q3 compared to 22.0
million EUR in Q3 FY 2002/3003. The recalculation is expected to
increase revenues and reduce net loss for the first nine months by 4
million EUR. As of December 31, 2003, LION had liquidity in the form
of cash, cash equivalents and marketable securities of 48.1 million
EUR.
LION expects to record revenues of 19 to 20 million EUR for the
current FY 2003/2004 due in part to the expected positive impact from
the previous year’s restatement. The on-going slump in the life
science informatics market, the weak U.S. dollar as well as a slower
than anticipated market introduction of new products, continue to
have an adverse effect on LION’s business. LION expects to have
liquidity of at least 40 million EUR by the end of the current FY
2003/2004. The net loss for the current fiscal year is expected to be
between 22 and 25 million EUR. LION expects to adjust its guidance
for FY 2004/2005 due in part to the planned restatement and to
announce these new targets without undue delay.
end of announcement        euro adhoc 04.02.2004

Further inquiry note:

Günter Dielmann
Tel: 06221 4038 249
guenter.dielmann@lionbioscience.com

Julia Fritz
Tel: 06221 4038 158
julia.fritz@lionbioscience.com

Branche: Pharmaceuticals
ISIN: DE0005043509
WKN: 504350
Index: Nemax 50, Prime Standard, TecDAX
Börsen: Frankfurter Wertpapierbörse / regulated dealing
New York / regulated dealing
Niedersächsische Börse zu Hannover / free trade
Berliner Wertpapierbörse / free trade
Bayerische Börse / free trade
Hamburger Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade